084650.KQ
LabGenomics Co., Ltd.
KOE · Healthcare · Medical - Specialties · KR
KRW 2,010.00
−0.25%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 77.6B | 88.2B | 85.9B | 71.1B | 144.8B |
| Cost of Revenue | 61.2B | 65.2B | 54.5B | 41.6B | 48.0B |
| Gross Profit | 16.4B | 23.0B | 31.4B | 29.5B | 96.8B |
| Operating Expenses | |||||
| R&D Expense | 1.3B | 1.9B | 2.7B | 2.6B | 1.9B |
| SG&A Expense | 22.3B | 16.6B | 17.6B | 13.1B | 9.3B |
| General & Admin Expense | 3.2B | 4.2B | 4.0B | 2.8B | 2.7B |
| Selling & Marketing Expense | 9.1B | 12.4B | 13.6B | 10.4B | 6.7B |
| Other Expenses | 33.2B | 59.4B | 29.6B | 17.0B | 19.3B |
| Total Operating Expenses | 56.5B | 77.9B | 49.9B | 32.7B | 30.6B |
| Cost and Expenses | 117.7B | 143.1B | 104.4B | 74.3B | 78.6B |
| Operating Income (EBIT) | (40.1B) | (54.9B) | (18.5B) | (3.2B) | 66.2B |
| Non-Operating | |||||
| Interest Income | 390.3M | 789.6M | 2.1B | 4.5B | 830.9M |
| Interest Expense | 6.2B | 5.7B | 5.5B | 5.0B | 574.0M |
| Net Interest Income | (5.8B) | (4.9B) | (3.4B) | (467.7M) | 256.9M |
| Other Non-Op Income/Expense | (3.4B) | (5.3B) | (7.5B) | (3.9B) | (2.8B) |
| Non-Operating Income (excl Interest) | 5.0B | — | 2.0B | 3.7B | 2.2B |
| EBT (Pre-Tax Income) | (43.5B) | (60.3B) | (26.0B) | (7.1B) | 63.4B |
| Income Tax Expense | 8.1B | 4.1B | (2.3B) | (1.8B) | 15.5B |
| Bottom Line | |||||
| Net Income | (51.6B) | (64.4B) | (23.8B) | (4.7B) | 48.4B |
| Earnings from Cont. Ops | (51.6B) | (64.4B) | (23.7B) | (5.3B) | 47.9B |
| Earnings from Discont. Ops | — | — | (212.8M) | 45.0M | — |
| Bottom Line Net Income | (51.6B) | (64.4B) | (23.8B) | (4.7B) | 48.4B |
| Per Share | |||||
| Basic EPS | (₩3,475) | (₩4,336) | (₩1,581) | (₩350) | ₩3,573 |
| Diluted EPS | (₩3,475) | (₩4,336) | (₩1,581) | (₩316) | ₩3,573 |
| Revenue Per Share | ₩5,229 | ₩5,938 | ₩5,707 | ₩5,322 | ₩10,687 |
| Shares | |||||
| Basic Shares Outstanding | 14.8M | 14.8M | 15.1M | 13.4M | 13.5M |
| Diluted Shares Outstanding | 14.8M | 14.8M | 15.1M | 14.8M | 13.5M |
| Profitability Metrics | |||||
| EBITDA | (58.7B) | (44.6B) | (10.8B) | 3.7B | 70.2B |
| D&A | 8.5B | 10.3B | 9.6B | 5.9B | 4.0B |
| EBIT | (67.3B) | (54.9B) | (20.4B) | (2.2B) | 66.2B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026